Enhanced antigen-specific antibody and cytokine responses when targeting antigen to human FcGAMMA receptor type I using an anti-human FcGAMMA receptor type I-streptavidin fusion protein in an adjuvant-free system.
There is a continuing need for alternatives to current human adjuvants. Recombinant protein vaccines, which target antigen to human Fc gamma receptor type I (hFcgammaRI) on hFcgammaRI-expressing antigen presenting cells, provide one potential alternative. Using a recombinant anti-hFcgammaRI-antigen fusion protein and adjuvant independent mouse model, we demonstrate enhanced antigen-specific antibody responses to low doses of antigen, when targeting antigen to hFcgammaRI in vivo. Enhanced antibody production to hFcyRI-targeted antigen is evident in both primary and secondary immune responses, as compared to that of non-targeted antigen. Furthermore, antibody isotype and cytokine responses following immunization with hFcgammaRI-targeted antigen, suggest enhancement of both Th1 and Th2 responses.
Adamova
Elisaveta
E
Center for Immunology and Microbial Disease, MC-151, Albany Medical College, Albany, NY 12208, USA.
Walsh
Mary C
MC
Gosselin
Diane R
DR
Hale
Karen
K
Preissler
Mark T
MT
Graziano
Robert F
RF
Gosselin
Edmund J
EJ
D000276:Adjuvants, Immunologic / Q000235:genetics*; D000818:Animals; D000917:Antibody Formation; D000941:Antigens / Q000276:immunology*; D016207:Cytokines / Q000096:biosynthesis*; D006801:Humans; D007114:Immunization; D007135:Immunoglobulin Variable Region / Q000235:genetics / Q000276:immunology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D017452:Receptors, IgG / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000276:immunology; D019809:Streptavidin / Q000235:genetics / Q000276:immunology
D000276:Adjuvants, Immunologic; D000941:Antigens; D016207:Cytokines; D007135:Immunoglobulin Variable Region; D017452:Receptors, IgG; D011993:Recombinant Fusion Proteins; D019809:Streptavidin